NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Core Points - NRx Pharmaceuticals, Inc. will release its third quarter 2025 financial results on November 17, 2025, before market opening [1] - A conference call will be held at 8:30am ET on the same day to provide corporate and financial updates [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [3] - The company is developing NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone [3] - NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression, while NRX-101 has been awarded Breakthrough Therapy Designation for suicidal bipolar depression [3] - NRx has recently re-filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100, applying for the Commissioner's National Priority Voucher Program [3]